Wednesday, September 16, 2026

Biotech & Pharmaceuticals

1 article

REGENXBIO Eyes 2027 Commercial Launch for Duchenne Gene Therapy as Pivotal Trial Wraps Enrollment

REGENXBIO has completed enrollment in its AFFINITY DUCHENNE pivotal trial for RGX-202, a gene therapy candidate for Duchenne Muscular Dystrophy, with top-line data expected in early Q2 2026 and a BLA submission targeting mid-2026. The company is positioning for a 2027 commercial launch backed by $302 million in liquidity and the industry's largest gene therapy bioreactor. Early clinical results show all four pivotal-dose patients exceeded expected functional outcomes with no serious adverse even

ViaNews Editorial Team (Finance)•Feb 18, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening

Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.

Our read on the data ›

Signals we're tracking

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,981

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,981 facts checked against source5,288 source documents archived

Query this data → isubstrate.com